Italy’s MolMed is close to presenting results from Phase III clinical trials of a new cancer treatment that could represent a turning point for the biotech company, its founder said on Wednesday.
Italy’s MolMed is close to presenting results from Phase III clinical trials of a new cancer treatment that could represent a turning point for the biotech company, its founder said on Wednesday.